 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Aidan Gilson (talk | contribs) 5 months ago. (Update) |
Ron A. Adelman | |
|---|---|
 Ron Adelman, Chair of the Department of Ophthalmology, Mayo Clinic in Jacksonville | |
| Alma mater | Tehran University of Medical Sciences (MD) University of California at Berkeley (MPH) Harvard Medical School, Massachusetts Eye & Ear Infirmary (Resident) Yale University School of Management (MBA) |
| Known for | Co-first author of the original laboratory paper on rhuFab VEGF (ranibizumab, Lucentis) |
| Scientific career | |
| Fields | Ophthalmology |
| Institutions | Mayo Clinic in Jacksonville, Florida |
Ron A. Adelman, MD, MPH, MBA, FACS, FARVO, is an ophthalmologist and academic, known for his contributions to retinal and macular disease research and surgery. He currently serves as the Chair of the Department of Ophthalmology at the Mayo Clinic in Jacksonville, Florida, effective March 1, 2024.[1]
Early Life and Education
editAdelman completed his undergraduate and medical education, followed by a Master of Public Health (MPH) from the University of California, Berkeley. He furthered his education with a Master of Business Administration (MBA) from the Yale School of Management. His medical training includes an ophthalmology residency and a fellowship in retinal surgery at Harvard Medical School, where he received numerous awards, including the Fellow of the Year in 2000 and the Club Vit Fellow Research Award.
Career
editAcademic and Medical Positions
editAdelman joined the Yale School of Medicine in 2001, initially as an Assistant Professor. He rose to the rank of Professor and served as the Interim Chair of the Department of Ophthalmology and Visual Science from 2014 to 2016.[2] He also held the position of Vice Chair of Academics and was the Director of the Retina and Macula Service at Yale.[3]
Leadership and Contributions
editAdelman has held significant leadership roles in various medical societies. He was the President of the Connecticut State Medical Society (CSMS) 2021-2022, the Connecticut Society of Eye Physicians and Surgeons (CSEP) 2014-2016, and the New Haven County Medical Association (NHCMA) 2017-2019. Nationally and internationally, he served as the Scientific Director of the European VitreoRetinal Society (EVRS) since 2014, a councilor of the American Academy of Ophthalmology (AAO), and the CME Chair of the Association for Research in Vision and Ophthalmology (ARVO).[4] Additionally, he is an examiner for the American Board of Ophthalmology.
Research and Innovations
editAdelman has been at the forefront of research in macular and retinal diseases. He is the co-first author of the original laboratory paper on ranibizumab (Lucentis), the first effective treatment for wet macular degeneration.[5] He has introduced novel surgeries for macular holes that are now utilized globally and has described several new disorders. His recent work includes pioneering research on stem cells to re-engineer ocular tissues.
Publications and Editorial Work
editWith over 500 publications and abstracts, Adelman has made substantial contributions to ophthalmology literature. He serves on the editorial boards of eight scientific journals, including the American Journal of Ophthalmology.[6]
Awards and Honors
editThroughout his career, Adelman has received numerous accolades: - Senior Honor Award from the American Society of Retina Specialists - Senior Achievement Award from the American Academy of Ophthalmology - Gold Fellow of the Association for Research in Vision and Ophthalmology - M. Bruce Shields Teaching Award - "Knight of the Blind" by the Lions of Connecticut for his outstanding work globally and throughout the state
Teaching and Mentorship
editAdelman is recognized for his commitment to education, having received the Bruce Shields Teaching Award and served as a thesis advisor for over 20 Yale medical students. His mentorship has influenced many students, residents, and faculty members.
References
edit- ^ "x.com". X (formerly Twitter). Retrieved 2024-06-03.
- ^ "Ron Adelman, MD, MPH, MBA, FACS". medicine.yale.edu. Retrieved 2024-06-03.
- ^ "Ron Adelman, MD, MPH, MBA, FACS Appointed as Vice Chair of Academics in the Department of Ophthalmology & Visual Science". medicine.yale.edu. Retrieved 2024-06-03.
- ^ "The Association for Research in Vision and Ophthalmology- Committees". www.arvo.org. Retrieved 2024-06-03.
- ^ Krzystolik, Magdalena G. (2002-03-01). "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti–Vascular Endothelial Growth Factor Antibody Fragment". Archives of Ophthalmology. 120 (3): 338. doi:10.1001/archopht.120.3.338. ISSN 0003-9950.
- ^ "American Journal of Ophthalmology Editorial Board".